Abbott has announced an agreement to acquire Visiogen, Inc. for $400 million in cash. This acquisition provides the company with a next-generation IOL technology that addresses presbyopia for cataract patients.

Visiogen’s accommodating IOL, called Synchrony, is designed to deliver improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and improving contrast sensitivity. The Synchrony accommodating IOL is a significant advancement in artificial lens technology and is designed to mimic accommodation.

Synchrony has received CE mark designation and has been available commercially in Europe since January 2009. It also is currently under review by the U.S. Food and Drug Administration.

Read ^[1] the release.